检索结果 - Ірина Давиденко

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy

    Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breas... 由 Kimberly Blackwell, Vladimir Semiglazov, Dmitriy Krasnozhon, Ірина Давиденко, L. Nelyubina, Roumen Nakov, G. Stiegler, Pritibha Singh, Arnd Schwebig, Simon Krämer, Nadia Harbeck

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Rilomet-1: an International Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin and Capecitabine (Ecx) As First Line Therapy in Patients with Advanced Met-Positive Gastric or Gastroesophageal Junction (G/Gej) Adenocarcinoma

    Rilomet-1: an International Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin and Capecitabine (Ecx) As First Line Ther... 由 David Cunningham, S-E. Al-Batran, Ірина Давиденко, David H. Ilson, A.M. Murad, Niall C. Tebbutt, Nigel Baker, Rajul K. Jain, Tien Hoang

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

    A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovar... 由 Rebecca Kristeleit, Ірина Давиденко, Vadim Shirinkin, Fatima El-Khouly, Igor Bondarenko, Michael J. Goodheart, В. А. Горбунова, C A Penning, Jack Shi, Xiangdong Liu, Robert Newton, Yufan Zhao, Janet Maleski, Lance Leopold, Russell J. Schilder

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study

    Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study 由 Amit M. Oza, Frédèric Selle, Ірина Давиденко, Jacob Korach, César Mendiola, Patricia Pautier, Ewa Chmielowska, Aristotelis Bamias, Andrea DeCensi, Zanete Zvirbule, Antonio González‐Martín, Roberto Hegg, Florence Joly, Claudio Zamagni, Angiolo Gadducci, Nicolas Martin, Stephen Robb, Nicoletta Colombo

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

    Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 rando... 由 Jan B. Vermorken, Jan Stöhlmacher-Williams, Ірина Давиденко, Lisa Licitra, Eric Winquist, Cristian Villanueva, Paolo Foa, Sylvie Rottey, Krzysztof Składowski, Makoto Tahara, Vasant R. Pai, Sandrine Faivre, C. Blajman, Arlene A. Forastiere, B. Stein, Kelly S. Oliner, Zhiying Pan, Bruce Allen Bach

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type <i>KRAS</i> Metastatic Colorectal Cancer

    Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type <i>KRAS</i> Metastatic Colorectal Cancer 由 Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith P. Mitchell, Ірина Давиденко, Joe Stephenson, Elena Élez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S. Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Recombinant Human Intestinal Trefoil Factor Oral Spray for Prevention of Oral Mucositis in Patients With Colorectal Cancer Who Are Receiving Fluorouracil-Based Chemotherapy

    Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Recombinant Human Intestinal Trefoil Factor Oral Spray for Prevention of Oral Mucositis in Patients With Colorectal... 由 Douglas E. Peterson, Nicholas P. Barker, L. I. Akhmadullina, Irina Rodionova, Н. З. Шерман, Ірина Давиденко, Galina N. Rakovskaya, E. Gotovkin, С. А. Шинкарев, М. В. Копп, Eugeny P. Kulikov, Vladimir Moiseyenko, Joseph M. Gertner, Igor Firsov, Tamara Tuleneva, A. O. Yarosh, Chee-Wai Woon

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

    Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial 由 Josep Tabernero, Rocio García‐Carbonero, James T. Cassidy, Alberto Sobrero, Eric Van Cutsem, Claus-Henning Köhne, Sabine Tejpar, Oleg Gladkov, Ірина Давиденко, Ramón Salazar, Л. Ю. Владимирова, Sergey Cheporov, Olga Burdaeva, Fernando Rivera, Leslie Samuel, Irina Bulavina, Vanessa Potter, Yu-Lin Chang, Nathalie A. Lokker, Peter J. O’Dwyer

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

    Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, dou... 由 Daniel V.T. Catenacci, Niall C. Tebbutt, Ірина Давиденко, André M. Murad, Salah‐Eddin Al‐Batran, David H. Ilson, Sergei Tjulandin, Evengy Gotovkin, Bogusława Karaszewska, Igor Bondarenko, Mohamedtaki Abdulaziz Tejani, Anghel Adrian Udrea, Mustapha Tehfé, Ferdinando De Vita, Cheryl Turkington, Rui Tang, Agnes Ang, Yilong Zhang, Tien Hoang, Roger Sidhu, David Cunningham

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity

    Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of... 由 Elizabeth Poplin, Harpreet Wasan, Lindsey Rolfe, Mitch Raponi, Tone Ikdahl, Igor Bondarenko, Ірина Давиденко, В. Ю. Бондарь, August Garin, Stefan Boeck, Steffen Ormanns, Volker Heinemann, Claudio Bassi, Thomas Ronald Jeffrey Evans, Roland E. Andersson, Hejin P. Hahn, Vince Picozzi, Adam P. Dicker, Elaina Mann, Cynthia Voong, Paramjit Kaur, Jeff Isaacson, Andrew R. Allen

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: